Endocannabinoids and related fatty acid derivatives in pain modulation

Chemistry and Physics of Lipids

Volumn 121, Issue 1-2, 2002, Pages 159-172

  Walker, J Michael ^a   Krey, Jocelyn F ^a   Chu, Constance J ^a   Huang, Susan M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Analgesia; Anandamide; Cannabinoid; Endocannabinoid; Pain; Receptor

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2 LINEOYLGLYCEROL; 2 PALMITOYLGLYCEROL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AMINO ACID DERIVATIVE; ANANDAMIDE; ANTINOCICEPTIVE AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; FATTY ACID DERIVATIVE; GLYCEROL DERIVATIVE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N ARACHIDONOYLDOPAMINE; NOLADIN; OLEAMIDE; PALMIDROL; RIMONABANT; UNCLASSIFIED DRUG; VIRODHAMINE;

ANTINOCICEPTION; BRAIN; CONFERENCE PAPER; DRUG EFFECT; DRUG INHIBITION; NOCICEPTION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN FUNCTION; SPINAL CORD;

ANIMALS; BIOLOGICAL MARKERS; ENDOCANNABINOIDS; FATTY ACIDS; FATTY ACIDS, UNSATURATED; HUMANS; NERVOUS SYSTEM; PAIN; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0037207087     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(02)00152-4     Document Type: Conference Paper

References (91)

1. Adams I.B., Compton D.R., Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284:1998;1209-1217.
2. Ameri A. The effects of cannabinoids on the brain. Prog. Neurobiol. 58:1999;315-348.
3. Beaulieul P., Bisognol T., Punwar S., Farquhar-Smith W.P., Ambrosino G., Di Marzo V., Rice A.S. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur. J. Pharmacol. 396:2000;85-92.
4. Beltramo N., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anadamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
5. Ben-Shabat S., Fride E., Sheskin T., Tamiri X., Rhee M.H., Vogel Z., Bisogno T., De Petro-cellis L., Di Marzo V., Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353:1998;23-31.
6. Bicher H.I., Mechoulam R. Pharmacological effects of two active constituents of marihua. Arch. Int. P. Aharmacodyn. Ther. 172:1968;24-31.
7. Bisogno X., Melck D., Bobrovl M.Y., Gretskaya N.M., Bezuglov V.V., De Petrocellis L., Di Marzo V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 351:2000;817-824.
8. Bloom A.S., Dewey W.L., Harris L.S., Brosius K.K. 9-nor-9β-hydroxyhexahydro-cannabinol a cannabinoid with potent antinociceptive activity: comparisons with morphine. J. Pharm. Exp. Ther. 200:1977;263-270.
9. Boger D.L., Patterson J.E., Guan X., Cravatt B.F., Lerner R.A., Gilula N.B. Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc. Natl. Acad. Sci. USA. 95:1998;4810-4815.
10. Burkey T.H., Quock R.M., Consroe P., Ehlert F.J., Hosohata Y., Roeske W.R., Yamamura H.I. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur. J. Pharmacol. 336:(2-3):1997;295-298.
11. Burstein S.H., Rossetti R.G., Yagen B., Zurier R.B. Oxidative metabolism of anandamide. Prostagland. Other Lipid Med. 61:1999;29-41.
12. Burstein S.H., Huang S.M., Petros T.J., Rossetti R.G., Walker J.M., Zurier R.B. Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem. Pharmacol. 64:2002;1147-1150.
13. 9-tetrahydrocannabinol in the rat and mouse. Psychopharmacology. 25:1972;275-280.
14. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
15. Calignano A., La Rana G., Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol. 419:2001;191-198.
16. Chapman V. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br. J. Pharmacol. 127:1999;1765-1767.
17. Cravatt B.F., Prospero-Garcia O., Siuzdak G., Gilula N.B., Henriksen S.J., Boger D.L., Lerner R.A. Chemical characterization of a family of brain lipids that induce sleep. Science. 268:1995;1506-1509.
18. Cravatt B.F., Giang O.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
19. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Licht-man A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA. 98:2001;9371-9376.
20. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483:2000;52-56.
21. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
22. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:(5090):1992;1946-1949.
23. Di Marzo V., Bisogno T., Sugiura T., Melck D., De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem. J. 331:1998;15-19.
24. Di Marzo V., Melck D., Orlando P., Bisogno T., Zagoory O., Birulco M., Vogel Z., De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 358:2001;249-255.
25. Dixon W.E. The pharmacology of cannabis. Indica Br. Med. J. 2:1899;1354-1357.
26. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
27. Fedorova I., Hashimoto A., Fecik R.A., Hedrick M.P., Hanus L.O., Boger D.L., Rice K.C., Basile A.S. Behavioral evidence for the interaction of oleamide with multiple neuro-transmitter systems. J. Pharmacol. Exp. Ther. 299:2001;332-342.
28. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513:2002;294-298.
29. Formukong E.A., Evans A.T., Evans F.J. Analgesic and anti-inflammatory activity of constituents of Cannabis saliva L. Inflammation. 12:1988;361-371.
30. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., LeFur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
31. Glass M., Northup J.K. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol. Pharmacol. 56:(6):1999;1362-1369.
32. Guan X., Cravatt B.F., Ehring G.R., Hall J.E., Boger D.L., Lerner R.A., Gilula N.B. The sleep-inducing lipid oleamide deconvolutes gap juction communication and calcium wave transmission in glial cells. J. Cell. Biol. 139:1997;1785-1792.
33. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA. 98:2001;3662-3665.
34. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
35. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221:1997;157-160.
36. Hohmann A.G., Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci. Lett. 252:1998;13-16.
37. Hohmann A.G., Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92:1999;1171-1175.
38. Hohmann A.G., Walker J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neuron in the lumbar dorsal horn of the rat. J. Neurophys. 81:1999;575-583.
39. Hohmann A.G., Martin W.J., Tsou K., Walker J.M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci. 56:1995;2111-2119.
40. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci. Lett. 257:1998;1-4.
41. Hohmann A.G., Briley E.M., Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 20:1999;17-25.
42. Hohmann A.G., Tsou K., Walker J.M. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Acta Pharmacologica Sinica. 12:1999;1132-1136.
43. Hohmann A.G., Neely M.H., Suplita R.L. II, Nackley A.G., Holmes P.V., Crystal J.D. Endocannabinoid mechanisms of stress-induced analgesia. Soc. Neurosci. Abs. 27:2001;621.
44. Huang S.M., Bisogno T., Petros T.J., Chang S.Y., Zavitsanos P.A., Zipkin R.E., Sivakumar R., Coop A., Maeda D.Y., De Petrocellis L., Burstein S., Di Marzo V., Walker J.M. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem. 276:2001;42639-42644.
45. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza R., Tognetto M., Petros T.J., Krey J.F., Chu C.J., Miller J.D., Davies S.N., Geppetti P., Walker J.M., Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA. 99:2002;8400-8405.
46. Huidobro-Toro J.P., Harris R.A. Brain lipids that induce sleep are novel modulators of 5-hydroxytryptamine receptors. Proc. Natl. Acad. Sci. USA. 93:1996;8078-8082.
47. Jacob J., Ramabadran K., Campos-Medeiros M.A. Pharmacological analysis of levo-nantradol antinociception in mice. J. Clin. Pharmacol. 21:1981;327S-333S.
48. Jaggar S.I., Hasnie F.S., Sellaturay S., Rice A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
49. Jonsson K.O., Vandevoorde S., Lambert D.M., Tiger G., Fowler C.J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br. J. Pharmacol. 133:2001;1263-1275.
50. 9-tetrahydrocannabinol in the rat. Eur. J. Pharmacol. 24:1973;1-7.
51. Kuehl F.A. Jr, Jacob T.A., Ganley O.H., Ormond R.E., Meisinger M.A.P. The identification of N-2(hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J. Am. Chem. Soc. 79:1957;5577-5578.
52. Lambert D.M., Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic. Curr. Med. Chem. 6:1999;757-773.
53. Lambert D.M., CiPaolo E.G., Sonveaux P., Kanyonyo M., Govaerts S.J., Hermans E., Bueb J., Delzenne N.M., Tschirhart E.J. Analogues and homologues of N-palmitoylethanola-mide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta. 1440:1999;266-274.
54. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bohme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 283:1999;401-404.
55. Lichtman A.H., Martin B.R. Spinal and supraspinal components of cannabinoid-induced anthiociception. J. Pharmacol. Exp. Ther. 258:1991;517-523.
56. 2-noradrenergic mechanism. Brain Res. 559:1991;309-314.
57. Liebeskind J.C., Paul L.A. Psychological and physiological mechanisms of pain. Ann. Rev. Psychol. 28:1977;41-60.
58. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
59. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by the cannabinoid WIN 55,212-2:correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16:1996;6601-6611.
60. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300:1996;227-236.
61. McAllister S.D., Griffin G., Satin L.S., Abood M.E. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. Pharmacol. Exp. Ther. 291:(2):1999;618-626.
62. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayeitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 291:(50):1995;83-90.
63. Mechoulam R., Fride E., Hanus L., Sheskin T., Bisogno T., Di Marzo V., Bayewitch M., Vogel Z. Anandamide may mediate sleep induction. Nature. 389:1997;25-26.
64. Mechoulam R., Fride E., Di Marzo V. Endocannabinoids. Eur. J. Pharmacol. 359:1998;1-18.
65. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
66. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster P.P., Leese A.B., Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301:(3):2002;1020-1024.
67. Prusakiewicz J., Kingsley P., Kozak K., Marnett L. Selective oxygenation of N-arachidonylglycine by cyclooxygenase-2. Biochem. Biophys. Res. Commun. 296:2002;612-617.
68. Richardson J.D., Aanonsen L., Hargreaves K.M. SR141716A a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:1997;R3-R4.
69. Richardson J.D., Aanonsen L., Hargreaves K.M. Antihyperalgesic effects of spinal cannabinoids. Eur. J. Pharmacol. 345:1998;145-153.
70. Richardson J.D., Aanonsen L., Hargreaves K.M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18:1998;451-457.
71. Sañudo-Peña M.C., Walker J.M. A novel neurotransmitter system involved in the control of motor behavior by the basal ganglia, in neuronal mechanisms for generating locomotor activity. Ann. New York Acad. Sci. 860:1998;475-479.
72. Sañudo-Peña M.C., Strangman N.M., Mackie K., Walker J.M., Tsou K. CB1 receptor localization in spinal cord and roots, dorsal root ganglion, and peripheral nerve. Acta Pharmacol. Sinica. 12:1999;1115-1120.
73. Schatz A.R., Lee M., Condie R.B., Pulaski J.T., Kaminski N.E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142:1997;278-287.
74. Schmid H.H., Berdyshev E.V. Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukotrienes Essent. Fatty Acids. 66:2002;363-376.
75. Sheskin T., Hanus L., Slager J., Vogel Z., Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain Cannabinoid receptor. J. Med. Chem. 40:1997;659-667.
76. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129:2000;227-230.
77. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:(1):1994;219-227.
78. 9-tetrahydrocannabinol THC. J. Pharmacol. Exp. Ther. 186:1973;646-655.
79. Strangman N.M., Walker J.M. The cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J. Neurophysiol. 82:1999;472-477.
80. Strangman N.M., Patrick S.L., Hohmann A.G., Tsou K., Walker J.M. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res. 813:1998;323-328.
81. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:(1):1995;89-97.
82. Thomas E.A., Carson M.J., Neal M.J., Sutcliffe J.G. Unique allosteric regulation of 5-hydroxytryptamine receptor mediated signal transduction by oleamide. Proc. Natl. Acad. Sci. USA. 95:1997;14115-14119.
83. Tsou K., Lowitz K.A., Hohmann A.G., Martin W.J., Hathaway C.B., Bereiter D.A., Walker J.M. Suppression of noxious stimulus-evoked expression of fos-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 70:1995;791-798.
84. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., Walker J.M. Immunohistochemical localization of cannabinoid CB1 receptors in rat central nervous system. Neuroscience. 83:1998;393-411.
85. Tsou K., Nogueron M.I., Muthian S., Sañudo-Peña M.C., Hillard C.J., Deutsch D.G., Walker J.M. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci. Lett. 254:1998;137-140.
86. Walker J.M., Huang S.M., Strangman N.M., Tsou K., Sañudo-Peña M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA. 96:1999;12198-12203.
87. Walker J.M., Huang S.M., Strangman N.M., Sañudo-Peña M.C. Identification of the role of endogenous cannabinoids in pain modulation: strategies and pitfalls. J. Pain. 1:2000;20-32.
88. Yaksh T.L. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21:1981;334S-340S.
89. Yost C.S., Leonoudakis D.J., Koblin D.D., Bornheim L.M., Gray A.T. Oleamide potentiates benzodiazepine-sensitive gammaaminobutyric acid receptor activity but does not alter minimum alveolar anesthetic concentration. Anesth. Analg. 86:1998;1294-1300.
90. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Botmer T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;5780-5785.
91. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.